Header Logo

Connection

CLIONA ROONEY to Recombinant Fusion Proteins

Back to Details
This is a "connection" page, showing publications CLIONA ROONEY has written about Recombinant Fusion Proteins.
CLIONA ROONEY
Connection Strength
1.310
Recombinant Fusion Proteins
  1. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther. 2011 Dec; 19(12):2133-43.
    View in: PubMed
    Score: 0.306
  2. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Cancer Immunol Res. 2019 03; 7(3):363-375.
    View in: PubMed
    Score: 0.129
  3. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
    View in: PubMed
    Score: 0.116
  4. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224.
    View in: PubMed
    Score: 0.115
  5. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther. 2017 01 04; 25(1):249-258.
    View in: PubMed
    Score: 0.112
  6. Can Treg elimination enhance NK cell therapy for AML? Blood. 2014 Jun 19; 123(25):3848-9.
    View in: PubMed
    Score: 0.094
  7. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006 Dec 01; 108(12):3890-7.
    View in: PubMed
    Score: 0.054
  8. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005 Nov; 12(5):933-41.
    View in: PubMed
    Score: 0.050
  9. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 2002 Mar 15; 99(6):2009-16.
    View in: PubMed
    Score: 0.040
  10. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015 Jun 18; 125(25):3905-16.
    View in: PubMed
    Score: 0.025
  11. Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Cytotherapy. 2014 Sep; 16(9):1257-69.
    View in: PubMed
    Score: 0.024
  12. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014 Jun 12; 123(24):3750-9.
    View in: PubMed
    Score: 0.023
  13. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014 Jun; 22(6):1211-1220.
    View in: PubMed
    Score: 0.023
  14. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994 Mar; 5(3):381-97.
    View in: PubMed
    Score: 0.023
  15. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014 Mar; 22(3):623-633.
    View in: PubMed
    Score: 0.023
  16. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 01; 118(23):6050-6.
    View in: PubMed
    Score: 0.019
  17. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy. 2011 Sep; 13(8):976-86.
    View in: PubMed
    Score: 0.019
  18. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010 Oct; 33(8):780-8.
    View in: PubMed
    Score: 0.018
  19. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010 Apr 01; 115(13):2695-703.
    View in: PubMed
    Score: 0.017
  20. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009 Nov 26; 114(23):4784-91.
    View in: PubMed
    Score: 0.017
  21. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18; 113(25):6392-402.
    View in: PubMed
    Score: 0.016
  22. Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function. Cancer Res. 2007 Sep 01; 67(17):8335-43.
    View in: PubMed
    Score: 0.015
  23. Targeting CD19 with genetically modified EBV-specific human T lymphocytes. Ann Hematol. 2002; 81 Suppl 2:S42-3.
    View in: PubMed
    Score: 0.010
  24. Induction of vigorous helper and cytotoxic T cell as well as B cell responses by dendritic cells expressing a modified antigen targeting receptor-mediated internalization pathway. J Immunol. 2000 Oct 15; 165(8):4581-91.
    View in: PubMed
    Score: 0.009
  25. Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1. Virology. 1995 Apr 20; 208(2):521-30.
    View in: PubMed
    Score: 0.006
  26. Expression of the BZLF1 latency-disrupting gene differs in standard and defective Epstein-Barr viruses. J Virol. 1989 Apr; 63(4):1721-8.
    View in: PubMed
    Score: 0.004
  27. Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J. 1989 Jan; 8(1):127-32.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.